8ALQ

The Solution Structure of the Triple Mutant Methyl-CpG-Binding Domain from MeCP2 that Binds to Asymmetrically Modified DNA

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.6 mM [U-100% 13C; U-100% 15N] Methyl-CpG-binding domain (MBD) of MeCP2	90% H2O/10% D2O	100 mM	6	1 atm	305	Bruker AVANCE 800
2	3D HNCO	0.6 mM [U-100% 13C; U-100% 15N] Methyl-CpG-binding domain (MBD) of MeCP2	90% H2O/10% D2O	100 mM	6	1 atm	305	Bruker AVANCE 800
3	3D HNCA	0.6 mM [U-100% 13C; U-100% 15N] Methyl-CpG-binding domain (MBD) of MeCP2	90% H2O/10% D2O	100 mM	6	1 atm	305	Bruker AVANCE 800
4	3D CBCA(CO)NH	0.6 mM [U-100% 13C; U-100% 15N] Methyl-CpG-binding domain (MBD) of MeCP2	90% H2O/10% D2O	100 mM	6	1 atm	305	Bruker AVANCE 800
5	3D HNCACB	0.6 mM [U-100% 13C; U-100% 15N] Methyl-CpG-binding domain (MBD) of MeCP2	90% H2O/10% D2O	100 mM	6	1 atm	305	Bruker AVANCE 800
6	3D 1H-13C NOESY aliphatic	0.6 mM [U-100% 13C; U-100% 15N] Methyl-CpG-binding domain (MBD) of MeCP2	90% H2O/10% D2O	100 mM	6	1 atm	305	Bruker AVANCE 800
7	3D 1H-15N NOESY	0.6 mM [U-100% 13C; U-100% 15N] Methyl-CpG-binding domain (MBD) of MeCP2	90% H2O/10% D2O	100 mM	6	1 atm	305	Bruker AVANCE 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	800

NMR Refinement
Method	Details	Software
simulated annealing		CNS

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	200
Conformers Submitted Total Number	10
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CNS		Brunger, Adams, Clore, Gros, Nilges and Read
2	structure calculation	CYANA		Guntert, Mumenthaler and Wuthrich
3	chemical shift assignment	CARA		Keller and Wuthrich
4	peak picking	Sparky		Goddard

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.